Ovarian Cancer

Latest News
February 20th 2025

Ovarian Cancer Remission Rates Remained Stable Before, After COVID-19 Pandemic

February 18th 2025

Ovarian Cancer Outcomes Linked to Preoperative Immunonutritional Status

February 12th 2025

High Prevalence of Sarcopenia Identified in Patients With Ovarian, Endometrial Cancer

February 5th 2025

Physician Gaps in Genetic Testing Knowledge May Impact Ovarian Cancer Care

February 3rd 2025

Olaparib Leads PARP Inhibitors in Boosting OS for Platinum-Sensitive Recurrent Ovarian Cancer

Ovarian Cancer Guideline Updates 2024

Ronald D. Alvarez, MD, MBA, analyzes recent changes to NCCN guidelines for ovarian cancer care and provides updates on the latest clinical trial data.

Ronald D. Alvarez, MD, MBA, analyzes recent changes to NCCN guidelines for ovarian cancer care and provides updates on the latest clinical trial data.
Video Interviews
View All
February 27th 2025

Diving into the COVID-19 Pandemic’s Impact on Ovarian Cancer, Remission Rates

November 7th 2024

Charting a Healthier Future: Improving Ovarian Cancer Survival for Black Women Through Dietary Adherence

November 5th 2024

Nourishing Survival: The Impact of Dietary Quality on Black Women With Ovarian Cancer

March 18th 2024

Closing Thoughts on the Current Ovarian Cancer Treatment Landscape

March 18th 2024

Harnessing Biomarkers & Molecular Profiling in Ovarian Cancer Treatment

February 12th 2021

Dr Whitney Goldsberry on the Future of PARP Inhibitors in Ovarian Cancer

February 6th 2021

Dr Whitney Goldsberry on Cost-Sharing Trends in PARP Inhibitors for Ovarian Cancer

December 30th 2020

Dr Bradley Monk Discusses Indications for PARP Inhibitors in Ovarian Cancer

December 28th 2020

Dr Bradley Monk on Response to PARP Inhibitors in Ovarian Cancer

December 26th 2020

Dr Bradley Monk on the Changing Regulatory Landscape of PARP Inhibitors

More News

Clinician holding box of niraparib | Image Credit: luchschenF - stock.adobe.com
January 28th 2025

Niraparib Extends PFS, Time to Next Treatment in Patients With EOC, Especially BRCA-Mutated Cases

Brooke McCormick
First-line maintenance (1LM) niraparib significantly extends progression-free survival (rwPFS) and time to next treatment (rwTTNT) in patients with epithelial ovarian cancer (EOC), with the greatest benefit observed in those considered homologous recombination-deficient (HRd) and those with BRCA-mutated (BRCAm) tumors.
Ovarian cancer awareness illustration | Image Credit: Queenmoonlite Studio - stock.adobe.com
January 23rd 2025

Real-World Study Highlights PARP Inhibitor Challenges in Ovarian Cancer Care

Brooke McCormick
Nearly half of patients with advanced ovarian cancer treated with first-line poly-ADP-ribose polymerase (PARP) inhibitors experienced recurrence in this real-world study, emphasizing the need for enhanced strategies to optimize postrecurrence treatment.
Surgeon team performing an operation | Image Credit: Georgii - stock.adobe.com
January 21st 2025

Gynecologic Oncology Practices Evolve With Surgical De-Escalation Trends

Brooke McCormick
Researchers identified a 15-year shift toward surgical de-escalation in gynecologic oncology, marked by fewer surgical interventions, increased adoption of minimally invasive techniques, and a greater focus on fertility preservation and sentinel lymph node procedures.
AI illustration | Image Credit: putilov_denis - stock.adobe.com
January 19th 2025

AI Outperforms Traditional Methods in Predicting Ovarian Cancer Surgery Outcomes

Brooke McCormick
Artificial intelligence (AI) models, particularly artificial neural networks and machine learning, outperform traditional methods in predicting post–complete cytoreduction outcomes in patients with ovarian cancer, including overall survival, no residual disease, and postoperative complications.
Ovarian cancer animation | Image Credit: MohammedElAmine - stock.adobe.com
January 16th 2025

High HSP60 Expression Signals Poor Prognosis, Aggressive Tumors in Ovarian Cancer

Brooke McCormick
High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a prognostic biomarker.
Physician holding niraparib box | Image Credit: luchschenF - stock.adobe.com
January 14th 2025

Niraparib Improves Outcomes in Patients With Stage III EOC, No Visible Residual Disease

Brooke McCormick
Patients with stage III epithelial ovarian cancer (EOC) and no visible residual disease after primary cytoreductive surgery had significantly longer real-world progression-free survival and time to next treatment when treated with first-line maintenance niraparib compared with those with higher-risk disease.
Ovarian cancer animation | Image Credit: Dr_Microbe - stock.adobe.com
January 9th 2025

Nomogram Predicts Overall Survival in Patients With Ovarian Cancer, Liver Metastases

Brooke McCormick
Researchers developed and validated a nomogram to predict 1-, 2-, and 3-year overall survival (OS) in patients with ovarian cancer and liver metastases (OCLM), outperforming an external model in stability and accuracy.
Image depicting the global population | Image Credit: flashmovie - stock.adobe.com
January 7th 2025

Global Trends in Ovarian Cancer Incidence Highlight Regional, Histological Variations

Brooke McCormick
Between 1988 and 2017, there were significant global variations and trends in ovarian cancer incidence and its subtypes, influenced by genetic, reproductive, and socioeconomic factors.
TOP 5 ovarian cancer articles of 2024 | Image Credit: Venngage
December 29th 2024

Top 5 Most-Read Ovarian Cancer Content of 2024

Brooke McCormick
The top 5 ovarian cancer articles of 2024 covered topics such as the impact of air pollution on ovarian cancer risk, treatment strategies for patients with liver metastases, and the benefits of early diagnosis through symptom-triggered testing.
Healthy lifestyle illustration | Image Credit: SkyLine - stock.adobe.com
December 23rd 2024

Exercise May Benefit Chemotherapy-Induced Peripheral Neuropathy in Patients With Ovarian Cancer

Brooke McCormick
Exercise interventions may help manage chemotherapy-induced peripheral neuropathy (CIPN) in patients with ovarian cancer through improved physical activity and muscle function, but evidence remains limited.
Dr Alice Lee
December 16th 2024

Addressing Ovarian Cancer Outcome Disparities With Cultural Understanding, Disaggregated Research

Brooke McCormick
In the final part of our interview, Alice W. Lee, PhD, MPH, highlights the importance of addressing ovarian cancer care disparities and beyond by understanding cultural and behavioral factors and adopting a more disaggregated approach to research.
Dr Alice Lee
December 13th 2024

Uncovering Factors Driving Survival in Hawaiian/Pacific Islander, Asian Indian/Pakistani Patients With Ovarian Cancer

Brooke McCormick
In part 2 of our interview, Alice W. Lee, PhD, MPH, of California State University, Fullerton, examines survival disparities between Hawaiian/Pacific Islander and Asian Indian/Pakistani patients with ovarian cancer and suggests areas for further research.
Dr Alice Lee
December 11th 2024

Revealing Ovarian Cancer Survival Gaps Among Asian American Subgroups

Brooke McCormick
Alice W. Lee, PhD, MPH, of California State University, Fullerton, discusses her study on ovarian cancer survival disparities among disaggregated Asian American subgroups, emphasizing the need for a subgroup-specific approach in cancer research.
3D illustration of ovarian cancer | Image Credit: Lars Neumann - stock.adobe.com
December 9th 2024

Individualized Niraparib Starter Dosing Cuts AE Costs in Ovarian Cancer by 48%

Brooke McCormick
Implementing an individualized starting dose (ISD) of niraparib (Zejula; GSK) reduced severe hematologic adverse event (AE) management costs by 48% compared with a fixed starting dose (FSD) in US patients with ovarian cancer.
European Commission headquarters | Image Credit: Andrzej - stock.adobe.com
November 28th 2024

European Commission Approves Mirvetuximab Soravtansine for FRα+ Platinum-Resistant Ovarian Cancer

Caroline Seymour
The European Commission has approved mirvetuximab soravtansine for select patients with pretreated folate receptor–alpha (FRα)-positive, platinum-resistant ovarian cancer.
FDA headquarters | Image Credit: Grandbrothers - stock.adobe.com
November 26th 2024

Avutometinib With Defactinib for Recurrent KRAS Mutant LGSOC Completes Rolling New Drug Application

Gillian McGovern
If approved, the combination regimen would be the first FDA-approved treatment for adults with recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC).
Palliative care | Image Credit: Chinnapong - stock.adobe.com
November 22nd 2024

Early Palliative Care Linked to Better End-of-Life Outcomes in Ovarian Cancer

Brooke McCormick
Initiating palliative care more than 3 months before death improves end-of-life outcomes for patients with ovarian cancer, highlighting the need for earlier interventions.
Female Asian patient at doctor | Image Credit: DragonImages - stock.adobe.com
November 13th 2024

Ovarian Cancer Survival Varies Widely Among Asian American Subgroups

Brooke McCormick
Researchers found significant differences in ovarian cancer survival among Asian American subgroups, emphasizing the importance of analyzing these groups separately.
HPV written in blocks | Image Credit: Iana Alter - stock.adobe.com
October 29th 2024

HPV 16 and 18 Linked to Ovarian Cancer Risk

Celeste Krewson
In a recent meta-analysis, the prevalence of human papillomavirus (HPV), especially types 16 and 18, was significantly increased among patients with ovarian cancer (OC) vs controls.
Balanced diet | Image Credit: nadianb - stock.adobe.com
October 24th 2024

Prediagnosis Diet Improves Survival in Black Women With Deadly Ovarian Cancer

Brooke McCormick
Moderate prediagnosis adherence to dietary guidelines was associated with improved survival rates among Black women with high-grade serous ovarian cancer, the most common and lethal type of ovarian cancer.
Patient with ovarian cancer | Image Credit: Kiattisak - stock.adobe.com
October 22nd 2024

Neoadjuvant Chemotherapy Becomes Leading Initial Treatment for Advanced Epithelial Ovarian Cancer

Brooke McCormick
By 2021, neoadjuvant chemotherapy followed by interval cytoreductive surgery became the most common initial treatment for patients with advanced epithelial ovarian cancer, overtaking primary cytoreductive surgery.
Air pollution | Image Credit: hramovnick - stock.adobe.com
October 18th 2024

Increased Ovarian Cancer Risk Linked to Elevated Nitrogen Dioxide Exposure, Study Finds

Brooke McCormick
Higher levels of ambient nitrogen dioxide may be linked to an increased incidence of ovarian cancer, while associations with other pollutants remain inconclusive.
3D ovarian cancer illustration | Image Credit: Dr_Microbe - stock.adobe.com
October 15th 2024

Mirvetuximab Soravtansine Effective in Patients With FRα+, Platinum-Sensitive Ovarian Cancer

Brooke McCormick
The phase 2 PICCOLO trial demonstrated that mirvetuximab soravtansine (Elahere; AbbVie) is effective and tolerable in heavily pre-treated patients with folate receptor alpha-positive (FRα+), platinum-sensitive ovarian cancer.
Mediterranean diet | Image Credit: fascinadora - stock.adobe.com
October 4th 2024

High Alternate Mediterranean Diet Scores Tied to Better Survival in Patients With Ovarian Cancer

Brooke McCormick
Higher pre- and postdiagnosis Alternate Mediterranean Diet (AMED) scores are associated with improved overall survival in patients with ovarian cancer.
National Ovarian Cancer Awareness Month | Image Credit: Rabin - stock.adobe.com
September 30th 2024

Ovarian Cancer Awareness Month: Prioritizing Early Detection, Bridging Equity Gaps

Brooke McCormick
September marked Ovarian Cancer Awareness Month, highlighting the importance of early detection and the need for equitable treatment access.
Ovarian cancer awareness ribbon | Image credit: SewcreamStudio - stock.adobe.com
September 27th 2024

5 Things to Know About Low-Grade Serous Ovarian Cancer

Pearl Steinzor
The first-ever Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day is dedicated to raising awareness, providing resources, and advocating for more research into this rare and recurrent form of ovarian cancer.
FDA office building | Image Credit: JHVEPhoto - stock.adobe.com
September 26th 2024

NXP800 Gains FDA Orphan Drug Status in ARID1a-Deficient Ovarian Cancers

Jordyn Sava
NXP800 was granted orphan drug designation from the FDA in ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers.
EMA logo | Image Credit: Ricochet64 - stock.adobe.com
September 25th 2024

CHMP Recommends Mirvetuximab Soravtansine for FRα+ Ovarian Cancer

Ashling Wahner
The European Medicines Agency's (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has recommended the marketing authorization of mirvetuximab soravtansine (Elahere; AbbVie) for folate receptor alpha–positive (FRα+), platinum-resistant epithelial ovarian cancer.
Ovarian cancer animation | Image Credit: Nuchjaree - stock.adobe.com
September 24th 2024

Olaparib/Cediranib Misses Survival End Points in Relapsed Ovarian Cancer Trial

Ashley Chan
Treatment with maintenance olaparib/cediranib demonstrated similar survival vs olaparib alone in platinum-sensitive relapsed ovarian cancer.
ovarian cancer animation | Image Credit: Lars Neumann - stock.adobe.com
September 21st 2024

Pan-Immune-Inflammation–Based Nomogram Predicts OS, PFS in Epithelial Ovarian Cancer

Brooke McCormick
Researchers developed a pan-immune-inflammation–based nomogram to accurately predict overall survival (OS) and progression-free survival (PFS) in patients with epithelial ovarian cancer
123456>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo